These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33831240)

  • 21. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
    Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
    Hsu YC; Ho HJ; Lee TY; Huang YT; Wu MS; Lin JT; Wu CY; El-Serag HB
    J Viral Hepat; 2018 May; 25(5):543-551. PubMed ID: 29193536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
    Teng YX; Li MJ; Xiang BD; Zhong JH
    Gut; 2020 Oct; 69(10):1900-1902. PubMed ID: 31843789
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
    Pol S; Luzivika Nzinga C; Fontaine H; Carrat F;
    Aliment Pharmacol Ther; 2021 Mar; 53(5):659. PubMed ID: 33566398
    [No Abstract]   [Full Text] [Related]  

  • 25. Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Yuan G; Yao J; Yu J; Xie X; He S
    Hepatology; 2021 Mar; 73(3):1240. PubMed ID: 33016343
    [No Abstract]   [Full Text] [Related]  

  • 26. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?
    Yuan BH; Zhu YK; Li RH
    Aliment Pharmacol Ther; 2020 Jan; 51(2):314-315. PubMed ID: 31880015
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
    van Erpecum KJ; Sonneveld MJ
    Eur J Intern Med; 2021 Jul; 89():27-29. PubMed ID: 34023149
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
    Marcellin P
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 2():S99-102. PubMed ID: 21095519
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
    Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
    PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Choi J; Kim GA; Han S; Lim YS
    Am J Gastroenterol; 2020 Mar; 115(3):406-414. PubMed ID: 31895708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management and treatment of patients with hepatitis B].
    den Eynde EV; Riveiro-Barciela M
    Enferm Infecc Microbiol Clin; 2016 Jul; 34 Suppl 3():47-51. PubMed ID: 27474247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
    Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
    Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
    Wang JG; Chen R; Wang LC
    Aliment Pharmacol Ther; 2021 May; 53(9):1048-1049. PubMed ID: 33831238
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.